Format

Send to

Choose Destination
Semin Arthritis Rheum. 2013 Oct;43(2):158-70. doi: 10.1016/j.semarthrit.2013.04.006.

Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics.

Author information

1
Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Center, Geert Grooteplein 26, 6525 GA Nijmegen, The Netherlands. Electronic address: w.vandenberg@reuma.umcn.nl.

Abstract

IMPORTANCE:

Accumulating evidence suggests that IL-17 A has broad pathogenic roles in multiple autoimmune and immune-mediated inflammatory diseases, including psoriasis and rheumatoid arthritis (RA). The development of new therapies that inhibit IL-17 pathway signaling is of clinical significance.

OBJECTIVES:

This review aims to summarize the current preclinical evidence on the role of Th17 cells and IL-17 and related cytokines in immune-mediated disease pathophysiology, with a focus on psoriasis and rheumatoid arthritis, as well as to summarize recent clinical trials in these indications with newly developed IL-17 pathway inhibitors.

METHODS:

A systematic literature search was conducted of PubMed using relevant keywords. Studies were assessed according to recent relevance to IL-17-mediated pathophysiology and clinical IL-17 inhibition. Experimental animal models of autoimmune disease and clinical studies that focused on IL-17 pathway inhibitors were included.

RESULTS:

Preclinical studies suggest that IL-17A is an attractive therapeutic target. Several IL-17A inhibitors have advanced into clinical trials, including the anti-IL-17A monoclonal antibodies, secukinumab and ixekizumab, and the anti-17RA monoclonal antibody brodalumab. Each has shown variable and sometimes favorable results in proof-of-concept and phase II clinical trials and is currently undergoing further clinical evaluation in a range of immune-mediated diseases.

CONCLUSION:

Targeting the IL-17 pathway shows promise as strategy to treat immune-mediated diseases ranging from skin to joints.

KEYWORDS:

Brodalumab; Interleukin-17; Ixekizumab; Secukinumab; Th17 cells

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center